Hawaii Biotech is developing vaccines against tick-borne encephalitis, malaria and Crimean-Congo haemorrhagic fever, chikungunya and Zika virus infections. The company plans to use its proprietary recombinant protein production platform to produce the subunit vaccines. The tick-borne encephalitis vaccine is being developed containing the tick-borne encephalitis envelope glycoprotein; the infection is caused by a virus that is a member of the family Flaviviridae. Hawaii Biotech is developing its malaria subunit vaccine in collaboration with researchers from the University of Hawaii-Manoa. Development is at the preclinical stage for the encephalitis, chikungunya virus, Zika virus infections and malaria vaccines, and under early research for the Crimean-Congo haemorrhagic fever virus infections vaccine, in the US.
As at July 2016, no recent reports of development had been identified for preclinical development in Encephalitis-virus-infections in USA (Parenteral), preclinical development in Malaria in USA (Parenteral).
As at March 2018, no recent reports of development had been identified for research development in Crimean-Congo-haemorrhagic-fever-virus-infections in USA (Parenteral).
As at March 2020, no recent reports of development had been identified for preclinical development in Zika-virus-infection in USA (Parenteral).
In November 2011, Merck and Co (via the subsidiary Merck Sharpe and Dohme) granted Hawaii Biotech an exclusive license to vaccine technology for tick-borne encephalitis and malaria, and a non-exclusive license for recombinant protein expression technology. These technologies were previously developed by Hawaii Biotech and acquired by Merck as part of a transaction in 2010  .
Key Development Milestones
In August 2016, Hawaii Biotech received a Small Business Innovation Research (SBIR) phase I grant from The National Institute of Allergy and Infectious Diseases, to develop a vaccine to protect against infection caused by the mosquito-borne chikungunya virus. Hawaii Biotech will be collaborating with Baylor College of Medicine and the Sabin Vaccine Institute on this joint award  .
In August 2009, Hawaii Biotech received a three-year Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Allergy and Infectious Disease (NIAID) to continue development of a vaccine to protect healthy subjects from tick-borne encephalitis. The company stated that the funding would enable completion of preclinical development and preparation for clinical trials of the vaccine. The funds would be used to establish safety, immunogenicity and efficacy of the vaccine in suitable animal models  .